What is Mabwell?
Mabwell (Shanghai) Bioscience is a values-based, R&D-driven biopharmaceutical company dedicated to advancing treatments across five key therapeutic areas: immunology, oncology, metabolic diseases, ophthalmology, and infectious diseases. The company has established a robust R&D infrastructure, featuring advanced platforms for new molecular discovery of hybridoma antibodies, B cell screening, ADC drug development, PEGylation technology, and bispecific antibody development. This comprehensive approach positions Mabwell to innovate in drug discovery, development, manufacturing, and commercialization.
How much funding has Mabwell raised?
Mabwell has raised a total of $825.9M across 2 funding rounds:
Series A
$278M
Stock Offering
$547.9M
Series A (2020): $278M with participation from Haitong Capital, Loyal Valley Capital, Oriental Fortune Capital, and Shenzhen Shiyu Investment Management
Stock Issuance/Offering (2022): $547.9M, investors not publicly disclosed
Key Investors in Mabwell
Haitong Capital
Haitong Capital is an investor in Mabwell's Series A funding round. Specific investment focus is not detailed.
Loyal Valley Capital
Loyal Valley Capital, a participant in Mabwell's Series A financing, likely focuses on strategic investments within the life sciences sector.
Oriental Fortune Capital
Oriental Fortune Capital, which provided backing during Mabwell's Series A, is presumed to invest in promising companies within the biotechnology and pharmaceutical industries.
What's next for Mabwell?
The recent major strategic investment signifies a pivotal moment for Mabwell (Shanghai) Bioscience, likely enabling the company to accelerate its pipeline development and expand its research and manufacturing capabilities. This substantial backing, characteristic of enterprise-level funding, suggests confidence from investors in Mabwell's innovative R&D engine and its potential to address significant unmet medical needs. The company is poised to leverage this capital for further growth and to solidify its position in the competitive biopharmaceutical landscape.
See full Mabwell company page
